Get notified of page updates
OlympiA - Olaparib Adjuvant Therapy for BRCA-related Breast Cancer
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Enroll in Research > Research Search & Enroll Tool > OlympiA - Olaparib Adjuvant Therapy for BRCA-related Breast Cancer
Printer Friendly Page OlympiA - Olaparib Adjuvant Therapy for BRCA-related Breast Cancer

OlympiA - Olaparib Adjuvant Therapy for BRCA-related Breast Cancer

Clinicaltrials.gov identifier:
NCT02032823

Treatment

Study Contact Information:

  • Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA 

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)

About the Study

The OlympiA trial is the first major study to test the olaparib (Lynparza) for people with mutation-associated breast cancer in the setting (after surgery) for people with earlier-stage ( 2 or 3) cancers. OlympiA is a phase III clinical trial looking at the safety and effectiveness of olaparib for women with 2 or 3 breast cancer with a mutation after they have completed standard therapy.

The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

This Study is Open To:

The study is no longer enrolling patients. 

This Study is Not Open To:

The study is no longer enrolling patients.